Maravai Q3 revenue $191.3M, down 7% YoY; net income $99.7M; guidance updated

MARAVAI LIFESCIENCES HOLDINGS, INC.

2022-Q3 EPS reported $1.37 revenue$678,288,000

Q3 revenue $191.3M (-6.6% YoY); net income $99.7M vs $132.2M prior year.
Adjusted EBITDA $132.5M (69% margin), down from $154.9M prior year.
Nucleic Acid Production revenue $174.9M, down 4% YoY; COVID-19 CleanCap revenue estimated $126.5M.
Biologics Safety Testing revenue $16.4M, down 1% YoY.
FY2022 guidance updated for revenue, Adjusted EBITDA, and Adjusted EPS; specific figures not provided in excerpt.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

MARAVAI LIFESCIENCES HOLDINGS, INC. reported third quarter ended September 30, 2022 results: revenue $191.3 million, net income $99.7 million.

Period: third quarter ended September 30, 2022
Revenue: $191.3 million
Net income: $99.7 million
Result: reported results

Exact text from the filing

Quarterly revenue of $191.3 million, Net income of $99.7 million, and Adjusted EBITDA margins of 69%;

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

MARAVAI LIFESCIENCES HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001823239-22-000056

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.